Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

KYTX

Kyverna Therapeutics (KYTX)

Kyverna Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KYTX
DateTimeSourceHeadlineSymbolCompany
18/06/202406:05PR Newswire (US)First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)NASDAQ:KYTXKyverna Therapeutics Inc
14/06/202420:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYTXKyverna Therapeutics Inc
11/06/202408:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYTXKyverna Therapeutics Inc
11/06/202406:05PR Newswire (US)Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews ImmunologyNASDAQ:KYTXKyverna Therapeutics Inc
08/06/202406:06PR Newswire (US)Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024NASDAQ:KYTXKyverna Therapeutics Inc
30/05/202406:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYTXKyverna Therapeutics Inc
15/05/202406:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KYTXKyverna Therapeutics Inc
15/05/202406:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYTXKyverna Therapeutics Inc
15/05/202406:05PR Newswire (US)Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:KYTXKyverna Therapeutics Inc
12/04/202407:01PR Newswire (US)Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesNASDAQ:KYTXKyverna Therapeutics Inc
30/03/202405:59PR Newswire (US)First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedNASDAQ:KYTXKyverna Therapeutics Inc
27/03/202407:05PR Newswire (US)Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:KYTXKyverna Therapeutics Inc
08/03/202411:26PR Newswire (US)Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple SclerosisNASDAQ:KYTXKyverna Therapeutics Inc
13/02/202408:39PR Newswire (US)Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:KYTXKyverna Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYTX